Literature DB >> 8809127

Low T cell reactivity to combined CD3 plus CD28 stimulation is predictive for progression to AIDS: correlation with decreased CD28 expression.

M T Roos1, F Miedema, A P Meinesz, N A De Leeuw, N G Pakker, J M Lange, R A Coutinho, P T Schellekens.   

Abstract

In 219 HIV-1-infected men of the Amsterdam cohort we measured CD4+ T cell numbers and in vitro T cell responses to CD3 MoAbs with or without CD28 costimulation and phytohaemagglutinin (PHA). The value of these markers was estimated for disease progression within 4 years. CD28 expression on T cells has been related to T cell responses. CD28 costimulation considerably enhanced T cell reactivity (approximately 8-10-fold) with lower coefficients of variation compared with reactivity to CD3 MoAb alone (median 5 versus 20). T cell reactivity to CD3 plus CD28 MoAb was decreased during HIV-1 infection and was besides CD4+ T cell numbers the only independent predictor for progression to AIDS. Compared with the group with high CD4+ T cell numbers the relative risk (RR) for the group with intermediate levels was 2.28, with low levels 5.20. In the groups with intermediate and low CD3 plus CD28 responses the RR was 2.04 and 4.16, respectively. The combined RR for both was 4.65 and 21.63. The independence of this marker was confirmed when the group with low CD4+ T cell numbers was subdivided into groups with high, intermediate and low T cell responses. The expansion of CD8+CD28- T cells was already apparent in HIV- homosexual men, but CD8+CD28+ T cells specifically decreased in patients with AIDS. CD28 expression on T cells correlated moderately with T cell responses to CD3 plus CD28 MoAb. T cell reactivity to CD3 MoAb in the presence of CD28 MoAb is a stronger prognostic marker than T cell reactivity to CD3 MoAb alone.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8809127      PMCID: PMC2200530          DOI: 10.1046/j.1365-2249.1996.d01-794.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  7 in total

1.  CD28 costimulation and CD28 expression in T lymphocyte subsets in HIV-1 infection with and without progression to AIDS.

Authors:  H Choremi-Papadopoulou; N Panagiotou; E Samouilidou; F Kontopidou; V Viglis; A Antoniadou; J Kosmidis; T Kordossis
Journal:  Clin Exp Immunol       Date:  2000-03       Impact factor: 4.330

2.  In vitro naïve T cell proliferation failure predicts poor post-immunization responses to neoantigen, but not recall antigens, in HIV-infection.

Authors:  Benigno Rodriguez; Hernan Valdez; Christoph G Lange; Robert Asaad; Kathy Medvik; Scott F Sieg
Journal:  Clin Immunol       Date:  2010-05-15       Impact factor: 3.969

3.  The CD28/HLA-DR expressions on CD4+T but not CD8+T cells are significant predictors for progression to AIDS.

Authors:  Byeong-Sun Choi; Yong-Keun Park; Joo-Shil Lee
Journal:  Clin Exp Immunol       Date:  2002-01       Impact factor: 4.330

4.  Lower CD4+ T lymphocyte nadirs may indicate limited immune reconstitution in HIV-1 infected individuals on potent antiretroviral therapy: analysis of immunophenotypic marker results of AACTG 5067.

Authors:  Ronald D'Amico; Yijun Yang; Donna Mildvan; Scott R Evans; Carol T Schnizlein-Bick; Richard Hafner; Nancy Webb; Michael Basar; Robert Zackin; Mark A Jacobson
Journal:  J Clin Immunol       Date:  2005-03       Impact factor: 8.317

5.  Nonradioactive techniques for measurement of in vitro T-cell proliferation: alternatives to the [(3)H]thymidine incorporation assay.

Authors:  T Messele; M T Roos; D Hamann; M Koot; A L Fontanet; F Miedema; P T Schellekens; T F Rinke de Wit
Journal:  Clin Diagn Lab Immunol       Date:  2000-07

6.  Neural networks in the assessment of HIV immunopathology.

Authors:  G Hatzakis; C Tsoukas
Journal:  Proc AMIA Symp       Date:  2001

7.  Differential production of IL-10 by T cells and monocytes of HIV-infected individuals: association of IL-10 production with CD28-mediated immune responsiveness.

Authors:  A Kumar; J B Angel; M P Daftarian; K Parato; W D Cameron; L Filion; F Diaz-Mitoma
Journal:  Clin Exp Immunol       Date:  1998-10       Impact factor: 4.330

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.